BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

Halozyme and argenx Secure FDA Nod for VYVGART® Hytrulo Prefilled Syringe for Self-Injection

Halozyme Therapeutics, Inc. announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syri...

April 11, 2025 | News

Lucence and HKPOS Launch Hong Kong’s First Study on Blood Test for Early Lung Cancer Detection

In a two-year collaboration with HKPOS, 600 lung cancer patients aged 45-74 in Hong Kong will be studied using Lucence's non-invasive liquid biopsy to as...

April 10, 2025 | News

Darnatein Secures First International Patent in China for AI-Engineered Osteoarthritis Drug Technology

Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international pat...

April 10, 2025 | News

China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the se...

April 08, 2025 | News

ABL Bio and GSK Sign Multi-Program Licensing Deal to Develop Neurodegenerative Therapies Using Grabody-B Platform

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL...

April 07, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU Approved in EU for Earlier Treatment of HER2 Low and Ultralow Breast Cancer

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free surviv...

April 04, 2025 | News

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Lunit Collaborates with U.S. National Cancer Institute to Advance AI-Driven Cancer Research

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the Nationa...

April 01, 2025 | News

Gene Solutions Achieves Landmark Validation for Asia’s First Clinically Proven Multi-Cancer Blood Test, SPOT-MAS

Gene Solutions, a leading biotech company in Asia, proudly announces a groundbreaking achievement in cancer early detection. Common cance...

March 27, 2025 | News

AnHorn Medicines Doses First Subject in U.S. Phase I Trial for AH-001, a First-in-Class Protein Degrader Targeting Hair Loss

AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class protein degrader for androg...